Ann: Quarterly Activities Report and Appendix 4C, page-15

In my mind, this was really a mistake - and a significant one - made by Atomo. Had they simply gone the route of selling the Covid test with the existing brand name then they could've made some quick and significant money. Instead, they chose to rebrand it as 'Atomo' and go through the different approval process.

Perhaps, they figured that the rapid testing needs would be ongoing (indefinitely) and the rebranding was both a way of diversifying the business and getting greater brand awareness. It turned out to be a costly mistake and a missed opportunity.

Their gamble (or strategy) on rapid testing Covid antibodies also failed and the product has been discontinued.

This is all said with a level of hindsight. I just hope they learn from these errors and some winds of good luck blow their way!